Testing radiation, chemo, and immune therapy for borderline pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new combination of radiation, chemotherapy, an immunotherapy drug (PD-1 inhibitor), and a medicine that boosts the immune system (thymalfasin) for people with pancreatic cancer that is just on the edge of being removable by surgery. The goal is to see if this treatment can shrink the tumor enough to make surgery possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and in good overall health (ECOG score 0-1).
- You have been diagnosed with a specific type of pancreatic cancer (ductal adenocarcinoma) that is borderline resectable.
- You have not had any prior chemotherapy, radiation, or other cancer treatment for this cancer.
- Your blood counts (neutrophils, hemoglobin, platelets) and liver/kidney function are within a certain healthy range.
- You are not pregnant or breastfeeding, and if you can have children, you agree to use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether giving chemotherapy before surgery, and possibly adding a focused high-dose radiation treatment, can improve outcomes for people with borderline resectable pancreatic cancer. It aims to shrink or control the cancer and help more patients get to surgery safely.
This trial tests a combination of chemotherapy drugs (AG and FOLFIRINOX) with an immunotherapy drug (PD-L1 antibody) to shrink pancreatic tumors that are borderline resectable or locally advanced, making them removable by surgery. It's for people who haven't had any previous cancer treatment.
This trial tests whether giving targeted radiation therapy first, followed by a combination chemotherapy (NALIRIFOX), is better than chemotherapy alone for people with pancreatic cancer that is borderline resectable. The goal is to see if the radiation helps shrink the tumor enough to make surgery possible.
This trial tests whether giving proton radiation and chemotherapy before surgery can shrink or control “borderline resectable” pancreatic cancer so it can be removed more effectively. It may help by improving treatment response while planning for surgery afterward.
This trial is testing a combination of three chemotherapy drugs (NALIRIFOX) given before surgery to shrink borderline resectable pancreatic cancer. The goal is to help make surgery more successful and improve outcomes.
This trial tests whether adding the drug IBI343 to chemotherapy before surgery can help people with borderline resectable pancreatic cancer. It is for those whose tumors have a specific protein called CLDN18.2 and have not spread to other parts of the body.
Hear when a new Carcinoma, Pancreatic Ductal trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.